ClinicalTrials.gov
public full text
Public Domain
5-HT3 Receptor Antagonist and Respiratory Drive in Patients With ARDS
This is a pilot study aimed at acquiring primary physiological data, describing and estimating the effects of a 5-HT3 receptor antagonist (ondansetron) on respiratory drive in patients with acute respiratory distress syndrome (ARDS). The results of this study will determine the interest and feasibility of assessing the clinical applications of ondansetron in reducing patient self-inflicted lung injury (P-SILI) in ARDS, in subsequent studies.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Biomarkers to Predict Acute Respiratory Distress Syndrome(ARDS) in Patients With Sepsis#332843
- Longitudinal Recovery Trajectories After an Acute Respiratory Distress Syndrome, a New Understanding#831062
- The ATG14–SIRT1 Axis Modulates NF-Κb Pathway Activation and Inflammatory Responses in Acute Lung Injury#391585
- Inflammation Severity and miRNA-126 in Trauma#804864
- Anti-inflammatory and antioxidant effects of taxifolin against sepsis-induced renal injury in mice#667776
Record · ID 868469
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive